The Case of the PARP Inhibitor Adherence Assistance
Mei is a 67-year-old patient who recently underwent an exploratory laparotomy, total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and tumor debulking. Her surgical specimens were sent for pathology review and germline biomarker testing. Based on the findings, Mei was diagnosed with stage IIIC, high-grade serous epithelial ovarian cancer with a BRCA1 pathogenic germline variant.
PARP Inhibitors and Ovarian Cancer
Before poly (adenosine diphosphate-ribose) polymerase inhibitors were approved for ovarian cancer, traditional treatment consisted of surgical cytoreduction and platinum-based chemotherapy with a taxane, with or without bevacizumab, depending on stage and type. With the surgery-chemotherapy combination, 70%–75% of patients had recurrence and overall five-year survival rate were 29%, indicating a need for additional therapies.
Nurse-Led Online Intervention Improves Symptoms, Control, and QOL in Ovarian Cancer
An eight-week online symptom self-management program, which can be facilitated by a nurse, significantly improves symptom burden, sense of control, and quality of life among patients with ovarian cancer. Researchers reported the evidence in the Journal of Clinical Oncology.
Precision Oncology Models Guide Tailored Nursing Interventions for Ovarian Cancer Symptom Clusters
Using the National Institutes of Health Symptom Science Model and Nursing Science Precision Health Model helps oncology nurses to recognize symptoms more promptly in patients with ovarian cancer and provide precision interventions that address racial disparities and foster equity in symptom-focused, patient-centered care, Mahoney and Pierce reported in the October 2022 issue of the Clinical Journal of Oncology Nursing.
Oncology Drug Reference Sheet: Pafolacianine
An optical imaging agent shown to improve diagnostic accuracy, pafolacianine (CytaluxTM) was approved on November 29, 2021, for use in adult patients with known or suspected ovarian cancer as adjunct therapy in conjunction with planned intraoperative identification of malignant lesions. Pafolacianine is used in combination with a near-infrared (NIR) fluorescence imaging system that requires specialized training provided by the device manufacturer.
Racial Minorities Receive More Aggressive EOL Ovarian Cancer Care
During the last month of life, non-White patients are more likely to receive aggressive care with little to no focus on palliative or end-of-life (EOL) care for their ovarian cancer, researchers reported in Cancer.
Latina, Asian Women With Gynecologic Cancers Are Less Likely to Use Palliative Care
Only 4%–9% of patients with ovarian or cervical cancer use palliative care, but the numbers are much lower for Hispanic and Asian women than for non-Hispanic White women, according to researchers’ findings reported in Data in Brief.
MicroRNA May Be Key Factor in High-Grade Ovarian Cancer Development
The miR-181a microRNA may turn off two genes and lead to the development of high-grade serous ovarian cancer, researchers reported in Nature Communications. The finding is significant because not much is known about how ovarian cancer develops and it’s difficult to detect in its earlier stages.
FDA Approves Olaparib Plus Bevacizumab as Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
On May 8, 2020, the U.S. Food and Drug Administration (FDA) expanded the indication of olaparib (Lynparza®) to include its combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line, platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)–positive status defined by either a deleterious or suspected deleterious BRCA mutation or genomic instability.
FDA Approves Niraparib for First-Line Maintenance of Advanced Ovarian Cancer
On April 29, 2020, the U.S. Food and Drug Administration (FDA) approved niraparib (Zejula®) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
Ovarian Cancer: Prevention, Screening, Treatment, and Survivorship Recommendations
Even though its incidence is less common, ovarian cancer is the fifth leading cause of death from cancer in women, according to the American Cancer Society. It also estimated more than 22,000 new cases of ovarian cancer in 2019, with a five-year survival of 47% for all stages.
The Case of the Belated BRCA Test
Eighteen months after completing surgical debulking and chemotherapy for stage III high-grade serous ovarian cancer, 56-year-old Lily experienced a rising CA-125 level. At her oncologist’s recommendation, Lily started an aromatase inhibitor, but it did not stop the rising tumor marker. After she began experiencing symptoms of bloating and mild abdominal pain, Lily and her oncologist decided to proceed with second-line chemotherapy. As she left the office, Lily remarked that she did not complete genetic testing when she was originally diagnosed because she does not have any children or a family history of ovarian cancer and she was concerned that her insurance would not cover the testing.
Recent NSAID Use May Improve Ovarian Cancer Survival
Researchers have found that use of nonsteroidal anti-inflammatory drugs (NSAIDs) after diagnosis appears to improve survival for patients with epithelial ovarian cancer. The study results were published in Lancet Oncology.
BRCA Mutations Point to Hereditary Breast and Ovarian Cancer Syndrome
Although all cancers have a genetic basis, a subset result from an inherited (i.e., germline) mutation that puts a person at increased risk for certain cancers. Unfortunately, the signs of hereditary cancer are often overlooked or misunderstood. Here’s what oncology nurses need to know about BRCA mutations, one of the more common mutations you’ll see in practice.
FDA Approves Rucaparib for Treatment of Recurrent Ovarian Cancer
On April 6, 2018, the U.S. Food and Drug Administration (FDA) approved rucaparib, a poly ADP-ribose polymerase inhibitor, for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
FDA Approves Olaparib Tablets for Maintenance Treatment in Ovarian Cancer
On August 17, 2017, the U.S. Food and Drug Administration granted regular approval to olaparib tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
Olaparib Does Not Decrease Quality-of-Life in Patients With Ovarian Cancer
Patients with platinum-sensitive relapsed (PSR) serous ovarian cancer (SOC) have poor survival outcomes, with the median progression-free survival (PFS) after chemotherapy less than six months in many patients. Based on results from the SOLO2 study that found that maintenance olaparib after response to chemotherapy resulted in a significant improvement in PFS compared to placebo (median PFS = 19.1 versus 5.5 months) in patients with germline BRCA mutation PSR SOC (hazard ratio [HR] = 0.30; 95% CI = 0.22–0.41; p < 0.0001), researchers assessed the impact of health-related quality-of-life (HRQOL). The researchers presented the study at the ASCO Annual Meeting.
FDA Approves Niraparib for Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
On March 27, 2017, the U.S. Food and Drug Administration (FDA) approved niraparib, a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
FDA Approves Rucaparib for Advanced Ovarian Cancer
FDA Recommends Against Ovarian Cancer Screening Tests
Maintenance Treatment May Prolong Progression-Free Survival in Ovarian Cancer
ONS Strategic Sponsor Approximately 15 percent of woman with ovarian cancer have a BRCA mutation and every year, many patients with ovarian cancer are not tested for a BRCA mutation. Family history and age are poor predictors of BRCA status in ovarian cancer patients, which is why it is so important for all women with ovarian cancer to be tested. BeBRCAware is a movement to raise awareness about the importance of genetic testing for a BRCA mutation in ovarian cancer.